The STK35 (Serine/Threonine Kinase 35) protein, also known as CLIK-1 or CILK1. is a member of the serine/threonine kinase family. It is encoded by the STK35 gene located on human chromosome 20q13.33. STK35 is structurally characterized by an N-terminal kinase domain and a C-terminal citron homology (CH) domain, which suggests roles in cytoskeletal regulation. Studies indicate its involvement in cellular processes such as mitosis, cell migration, and actin cytoskeleton dynamics. For instance, STK35 interacts with HSPBAP1 to modulate actin filament organization and may influence cancer cell proliferation and metastasis. Dysregulation of STK35 has been linked to diseases, including colorectal cancer, hepatocellular carcinoma, and inflammatory conditions, though its precise mechanisms remain under investigation.
Antibodies targeting STK35 are essential tools for detecting its expression, localization, and functional interactions. These antibodies (e.g., polyclonal or monoclonal clones like EPR19931) are validated for techniques such as Western blotting, immunofluorescence, and immunohistochemistry. They help identify STK35’s tissue-specific expression patterns, such as elevated levels in certain cancers or immune cells. Researchers also use these antibodies to explore STK35’s role in signaling pathways, including its potential cross-talk with the Hippo-YAP pathway. Specificity is confirmed via knockdown/knockout controls. Commercial antibodies are available from suppliers like Abcam, Sigma-Aldrich, and Cell Signaling Technology, often with species reactivity spanning humans, mice, and rats. Ongoing studies aim to clarify STK35’s dual roles as a context-dependent oncogene or tumor suppressor and its therapeutic potential.